- Home
- PTNM vs NGNE Comparison
PTNM vs NGNE Comparison
Compare PTNM & NGNE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PTNM
- NGNE
- Stock Information
- Founded
- PTNM 2013
- NGNE 2003
- Country
- PTNM Hong Kong
- NGNE United States
- Employees
- PTNM N/A
- NGNE N/A
- Industry
- PTNM
- NGNE Biotechnology: Pharmaceutical Preparations
- Sector
- PTNM
- NGNE Health Care
- Exchange
- PTNM Nasdaq
- NGNE Nasdaq
- Market Cap
- PTNM 320.2M
- NGNE 325.3M
- IPO Year
- PTNM 2025
- NGNE N/A
- Fundamental
- Price
- PTNM $1.85
- NGNE $18.48
- Analyst Decision
- PTNM
- NGNE Strong Buy
- Analyst Count
- PTNM 0
- NGNE 7
- Target Price
- PTNM N/A
- NGNE $41.86
- AVG Volume (30 Days)
- PTNM 3.3M
- NGNE 110.1K
- Earning Date
- PTNM 01-01-0001
- NGNE 08-11-2025
- Dividend Yield
- PTNM N/A
- NGNE N/A
- EPS Growth
- PTNM N/A
- NGNE N/A
- EPS
- PTNM 0.05
- NGNE N/A
- Revenue
- PTNM $9,644,233.00
- NGNE N/A
- Revenue This Year
- PTNM N/A
- NGNE N/A
- Revenue Next Year
- PTNM N/A
- NGNE N/A
- P/E Ratio
- PTNM $32.65
- NGNE N/A
- Revenue Growth
- PTNM 9.87
- NGNE N/A
- 52 Week Low
- PTNM $0.98
- NGNE $6.88
- 52 Week High
- PTNM $14.79
- NGNE $74.49
- Technical
- Relative Strength Index (RSI)
- PTNM N/A
- NGNE 35.93
- Support Level
- PTNM N/A
- NGNE $19.59
- Resistance Level
- PTNM N/A
- NGNE $20.46
- Average True Range (ATR)
- PTNM 0.00
- NGNE 1.23
- MACD
- PTNM 0.00
- NGNE -0.20
- Stochastic Oscillator
- PTNM 0.00
- NGNE 13.37
About PTNM Pitanium Limited Class A Ordinary shares
Pitanium Ltd is a retailer in Hong Kong focusing on the sale of its proprietary brand of skincare and personal care products, especially haircare products, namely PITANIUM and BIG PI online and offline with six retail stores situated in Prime shopping destinations in Hong Kong. The company emphasizes product design and development with an in-house product development team working closely with its original equipment manufacturing (OEM) and original design manufacturing (ODM) suppliers.
About NGNE Neurogene Inc.
Neurogene Inc is a clinical-stage biotechnology company committed to overcoming the limitations of neurological diseases into treatable conditions, by harnessing its proprietary transgene regulation technology, EXACTTM (Expression Attenuation via Construct Tuning). It is building a differentiated product portfolio of genetic medicines for rare neurological diseases with high unmet needs. The drug candidates in the company's product pipeline include NGN-401, which is in development for the treatment of Rett syndrome, using its EXACT platform, and NGN-101, a non-EXACT, conventional gene therapy development candidate for the treatment of CLN5 Batten disease, designed to deliver the CLN5 gene and packaged in an AAV9 capsid.